State Street
CLDI icon

State Street’s Calidi Biotherapeutics CLDI Stock Holding History

State Street’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,108
Closed -$14.1K – 4303
2025
Q2 		$14.1K Hold
5,108
– – ﹤0.01% 4225
2025
Q1 		$34.7K Buy
5,108
+3,209
+169% +$36.6K ﹤0.01% 4140
2024
Q4 		$26.2K Buy
+1,899
New +$35.6K ﹤0.01% 4199
2024
Q3 		– Sell
-108
Closed -$2.58K – 4301
2024
Q2 		$2.58K Buy
+108
New +$3.45K ﹤0.01% 4358

Other funds holding CLDI

HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

State Street's CLDI Position: Q3 2025 in Review

State Street sold out of Calidi Biotherapeutics (CLDI) in Q3 2025, closing a stake of 5,108 shares — an estimated $14.1K sold.

State Street first reported a position in CLDI in Q2 2024 and held it in 4 quarters. The position peaked at $34.7K in Q1 2025. 22 funds tracked by Wall St. Rank hold CLDI as of Q3 2025.

  • State Street reported no remaining Calidi Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • State Street sold 5,108 Calidi Biotherapeutics shares in Q3 2025, an estimated $14.1K.
  • State Street first reported a position in Calidi Biotherapeutics in Q2 2024 and held it in 4 quarters.
  • State Street's Calidi Biotherapeutics position peaked at $34.7K in Q1 2025.
  • 22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2025.

Based on State Street's 13F filing for Q3 2025, filed 14 Nov 2025.